| Name | Title | Contact Details |
|---|
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company`s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion`s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
Revolutionary Products for Soft Tissue Replacement and Regeneration
VisionGate, Inc., is a clinical stage oncology pharmaceutical and diagnostics company with a focus on the early detection and treatment of lung cancer and bronchial dysplasia.
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations.